Advisor Group Holdings, Inc. Neurocrine Biosciences Inc Transaction History

Advisor Group Holdings, Inc.

$67.1 Billion
Q3 2025

A detailed history of Advisor Group Holdings, Inc. transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Advisor Group Holdings, Inc. holds 4,382 shares of NBIX stock, worth $634,776. This represents 0.0% of its overall portfolio holdings.

Number of Shares

4,382

Previous 5,031 12.9%

Holding current value

$634,776

Previous $632,000 2.69%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	SELL	$123.98 - $146.67 $80,463 - $95,188	-649 Reduced 12.9%	4,382 $615,000
Q2 2025 Sep 04, 2025	BUY	$87.54 - $128.18 $102,684 - $150,355	1,173 Added 30.4%	5,031 $632,000
Q2 2025 Aug 13, 2025	SELL	$87.54 - $128.18 $37,904 - $55,501	-433 Reduced 10.09%	3,858 $484,000
Q1 2025 May 12, 2025	SELL	$107.22 - $153.29 $214,654 - $306,886	-2,002 Reduced 31.81%	4,291 $474,000
Q4 2024 Jun 06, 2025	SELL	$111.62 - $139.44 $60,386 - $75,437	-541 Reduced 12.61%	3,750 $511,000
Q4 2024 Feb 07, 2025	BUY	$111.62 - $139.44 $27,346 - $34,162	245 Added 4.05%	6,293 $858,000
Q3 2024 Nov 13, 2024	BUY	$114.58 - $153.15 $19,822 - $26,494	173 Added 2.94%	6,048 $696,000
Q2 2024 Aug 13, 2024	SELL	$130.86 - $143.19 $1.04 Million - $1.14 Million	-7,975 Reduced 57.58%	5,875 $808,000
Q1 2024 May 10, 2024	BUY	$130.4 - $143.74 $547,419 - $603,420	4,198 Added 43.49%	13,850 $1.91 Million
Q4 2023 Feb 12, 2024	BUY	$106.07 - $132.76 $14,955 - $18,719	141 Added 1.48%	9,652 $1.27 Million
Q3 2023 Nov 13, 2023	BUY	$94.02 - $117.1 $194,621 - $242,397	2,070 Added 27.82%	9,511 $1.07 Million
Q2 2023 Aug 10, 2023	SELL	$89.53 - $104.87 $485,163 - $568,290	-5,419 Reduced 42.14%	7,441 $701,000
Q1 2023 May 12, 2023	SELL	$94.11 - $123.02 $71,805 - $93,864	-763 Reduced 5.6%	12,860 $1.3 Million
Q4 2022 Feb 10, 2023	SELL	$106.72 - $127.06 $24,652 - $29,350	-231 Reduced 1.67%	13,623 $1.63 Million
Q3 2022 Nov 14, 2022	BUY	$92.03 - $107.81 $324,773 - $380,461	3,529 Added 34.18%	13,854 $1.47 Million
Q2 2022 Aug 10, 2022	BUY	$75.79 - $100.07 $21,145 - $27,919	279 Added 2.78%	10,325 $1.01 Million
Q1 2022 May 04, 2022	SELL	$72.45 - $94.81 $18,402 - $24,081	-254 Reduced 2.47%	10,046 $1.06 Million
Q3 2021 Nov 05, 2021	BUY	$86.18 - $99.03 $82,129 - $94,375	953 Added 10.2%	10,300 $990,000
Q2 2021 Aug 02, 2021	BUY	$89.43 - $102.27 $42,658 - $48,782	477 Added 5.38%	9,347 $910,000
Q1 2021 May 13, 2021	BUY	$87.57 - $119.4 $86,431 - $117,847	987 Added 12.52%	8,870 $863,000
Q4 2020 Feb 10, 2021	SELL	$86.91 - $108.33 $37,023 - $46,148	-426 Reduced 5.13%	7,883 $755,000
Q3 2020 Nov 12, 2020	BUY	$96.16 - $135.15 $370,216 - $520,327	3,850 Added 86.34%	8,309 $807,000
Q2 2020 Aug 14, 2020	SELL	$85.09 - $130.36 $204,556 - $313,385	-2,404 Reduced 35.03%	4,459 $531,000
Q1 2020 May 18, 2020	BUY	$75.11 - $113.76 $515,479 - $780,734	6,863 New	6,863 $243,000

Others Institutions Holding NBIX

# of Institutions

723

Shares Held

102M

Call Options Held

230K

Put Options Held

477K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $13.9B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Advisor Group Holdings, Inc. with notifications on news.

Account

Advisor Group Holdings, Inc. Neurocrine Biosciences Inc Transaction History